The burgeoning popularity of semaglutide , initially for diabetes , is creating significant buzz within the British Isles, prompting a notable shift in hormone trends. Availability these treatments remains a complex landscape, with public healthcare system provision currently limited and independent providers offering therapy at a higher cost . Con